Related Experiment Video
Updated: May 16, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Prothrombotic polymorphisms in patients with Raynaud's phenomenon and migraine
A T Takáts1, Amir-Houshang Shemirani, K S Zsóri
1Semmelweis University 1st Department of Surgery Budapest Hungary.
Acta Physiologica Hungarica
|December 15, 2012
Summary
Methyltetrahydrofolate reductase T677 allele is more prevalent in primary Raynaud's phenomenon patients who also experience migraine. Other inherited prothrombotic factors showed no significant association with migraine in this patient group.
Area of Science:
- Genetics
- Vascular Medicine
- Neurology
Background:
- Primary Raynaud's phenomenon (PRP) and migraine are common conditions.
- Inherited prothrombotic risk factors are associated with thrombotic events.
- The interplay between PRP, migraine, and thrombophilia is not fully understood.
Purpose of the Study:
- To investigate the prevalence of inherited prothrombotic risk factors in patients with primary Raynaud's phenomenon (PRP).
- To determine the association between these genetic factors and the co-occurrence of migraine in PRP patients.
Main Methods:
- Genotypic analysis was performed for FVLeiden, prothrombin G20210A, methyltetrahydrofolate reductase C677T, and FXIII-A V34L mutations.
- Two hundred Hungarian patients with PRP were included, categorized by the presence or absence of migraine.
- Statistical analysis was used to compare allele frequencies and clinical characteristics.
Main Results:
- The prevalence of the methyltetrahydrofolate reductase (MTHFR) C677T T677 allele was significantly higher in PRP patients with migraine compared to those without migraine (OR 2.1, p=0.001).
- The duration of PRP was significantly longer in patients who also experienced migraine.
- No significant differences in the prevalence of FVLeiden, prothrombin G20210A, or FXIII-A V34L mutations were observed between the migraine and non-migraine groups.
Conclusions:
- The MTHFR C677T polymorphism may be associated with an increased risk of migraine in patients with primary Raynaud's phenomenon.
- FVLeiden, prothrombin G20210A, and FXIII-A V34L mutations do not appear to influence the occurrence of migraine in PRP patients.
- Further research is warranted to elucidate the mechanisms linking MTHFR genotype to migraine in PRP.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...